Evid Invest
Holders — by stockHoldings — by fund

Merck & Co., Inc.

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0000310158

$526.4M

disclosed book value

13

positions

35.8%

largest position share

Positions, as of 2026-06-30

top 13 of 13 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#IssuerSharesValue% of book
1PSNLPERSONALIS INC14.0M$188.2M35.8%
2MRNAMODERNA INC2.3M$161.6M30.7%
3KYMRKYMERA THERAPEUTICS INC772,165$88.5M16.8%
4AKTSAKTIS ONCOLOGY INC952,844$30.7M5.8%
5EIKNEIKON THERAPEUTICS INC1.7M$21.7M4.1%
6TRDAENTRADA THERAPEUTICS INC1.7M$12.8M2.4%
7STROSUTRO BIOPHARMA INC272,351$9.0M1.7%
8ALECALECTOR INC3.5M$7.1M1.4%
9EVAXEVAXION BIOTECH A/S1.2M$3.8M0.7%
10VRDNVIRIDIAN THERAPEUTICS INC93,414$1.7M0.3%
11XLOXILIO THERAPEUTICS INC105,982$1.0M0.2%
12HURATUHURA BIOSCIENCES INC19,445$45,5010%
13NEUPNEUPHORIA THERAPEUTICS INC10,027$43,8180%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.

EvidInvest is an independent research and information tool. Figures are calculated from public SEC filings and third-party market data and are provided for informational and educational purposes only. EvidInvest does not provide investment advice, brokerage, or financial services, and is not affiliated with any company it covers. Verify all figures against primary sources before making any decision.